AU2015219920B2 - Triazine compound and use thereof for medical purposes - Google Patents
Triazine compound and use thereof for medical purposes Download PDFInfo
- Publication number
- AU2015219920B2 AU2015219920B2 AU2015219920A AU2015219920A AU2015219920B2 AU 2015219920 B2 AU2015219920 B2 AU 2015219920B2 AU 2015219920 A AU2015219920 A AU 2015219920A AU 2015219920 A AU2015219920 A AU 2015219920A AU 2015219920 B2 AU2015219920 B2 AU 2015219920B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- compound
- mmol
- mixture
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 C(C1)C=C1C1C*CC1 Chemical compound C(C1)C=C1C1C*CC1 0.000 description 8
- QYSBFTLRSZNPRR-UHFFFAOYSA-N CC(C)(C(F)(F)F)C(NCc(cc1)cc(-c2nc(C)nc(-c3cc(Cl)c(C)cc3)n2)c1Cl)=O Chemical compound CC(C)(C(F)(F)F)C(NCc(cc1)cc(-c2nc(C)nc(-c3cc(Cl)c(C)cc3)n2)c1Cl)=O QYSBFTLRSZNPRR-UHFFFAOYSA-N 0.000 description 1
- ZFZPVYUOJHBLFC-UHFFFAOYSA-N CC(C)(C(F)(F)F)C(NCc(cc1)cc(C2=CCCC(c3ccc(C)cc3)=NC(OC)=N2)c1Cl)=O Chemical compound CC(C)(C(F)(F)F)C(NCc(cc1)cc(C2=CCCC(c3ccc(C)cc3)=NC(OC)=N2)c1Cl)=O ZFZPVYUOJHBLFC-UHFFFAOYSA-N 0.000 description 1
- JDNXYRNIXVNRLN-UHFFFAOYSA-N CC(C)(C)C(CC1)CCC1(CO)C(O)=C Chemical compound CC(C)(C)C(CC1)CCC1(CO)C(O)=C JDNXYRNIXVNRLN-UHFFFAOYSA-N 0.000 description 1
- RMJUIEDQCZUQJZ-UHFFFAOYSA-N CC(C)C(C=C(C1)C2=NC(OC)=NC(Cl)=C(C)CC2)=C1C(F)(F)F Chemical compound CC(C)C(C=C(C1)C2=NC(OC)=NC(Cl)=C(C)CC2)=C1C(F)(F)F RMJUIEDQCZUQJZ-UHFFFAOYSA-N 0.000 description 1
- QPHATJBENHGMHE-UHFFFAOYSA-N CC(C)COc(cc1)ccc1-c1nc(-c(cc(CNC(C2(CC2)C(F)(F)F)=O)cc2)c2Cl)nc(O)n1 Chemical compound CC(C)COc(cc1)ccc1-c1nc(-c(cc(CNC(C2(CC2)C(F)(F)F)=O)cc2)c2Cl)nc(O)n1 QPHATJBENHGMHE-UHFFFAOYSA-N 0.000 description 1
- QMSYHWBCYJFWQB-UHFFFAOYSA-N CC(C)c1cc(BOC(C)(C)C(C)(C)O)ccc1C(F)(F)F Chemical compound CC(C)c1cc(BOC(C)(C)C(C)(C)O)ccc1C(F)(F)F QMSYHWBCYJFWQB-UHFFFAOYSA-N 0.000 description 1
- RNVNECSWWSBEPP-UHFFFAOYSA-N CC(C)c1cc(C2=NC(OC)=NC(c(cc(CO)cc3)c3Cl)=C(C)CC2)ccc1C(F)(F)F Chemical compound CC(C)c1cc(C2=NC(OC)=NC(c(cc(CO)cc3)c3Cl)=C(C)CC2)ccc1C(F)(F)F RNVNECSWWSBEPP-UHFFFAOYSA-N 0.000 description 1
- BHJMJHQMSARSCW-UHFFFAOYSA-N CC(CCC(c1cc(Cl)c(C)cc1)=N1)C(c(cc(CNC(C(C)(C)C(F)(F)F)=O)cc2)c2Cl)N=C1O Chemical compound CC(CCC(c1cc(Cl)c(C)cc1)=N1)C(c(cc(CNC(C(C)(C)C(F)(F)F)=O)cc2)c2Cl)N=C1O BHJMJHQMSARSCW-UHFFFAOYSA-N 0.000 description 1
- YUGLBCFVUQDIBB-UHFFFAOYSA-N CCC1(C(C)(C)C(N)=O)[F]=C1C Chemical compound CCC1(C(C)(C)C(N)=O)[F]=C1C YUGLBCFVUQDIBB-UHFFFAOYSA-N 0.000 description 1
- ZGOYJMRCAOKAAV-UHFFFAOYSA-N COC(NC(C1)C(C=C2)=CC(C3CC3)C2F)=NC1c(cc(CN)cc1)c1Cl Chemical compound COC(NC(C1)C(C=C2)=CC(C3CC3)C2F)=NC1c(cc(CN)cc1)c1Cl ZGOYJMRCAOKAAV-UHFFFAOYSA-N 0.000 description 1
- KDVZJKOYSOFXRV-UHFFFAOYSA-N Cc1ccc(B(O)O)cc1C Chemical compound Cc1ccc(B(O)O)cc1C KDVZJKOYSOFXRV-UHFFFAOYSA-N 0.000 description 1
- OMQUJFBGPRFTIO-UHFFFAOYSA-N OB(c(cc(CO)cc1)c1Cl)O Chemical compound OB(c(cc(CO)cc1)c1Cl)O OMQUJFBGPRFTIO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014-031035 | 2014-02-20 | ||
| JP2014031035 | 2014-02-20 | ||
| PCT/JP2015/054519 WO2015125842A1 (ja) | 2014-02-20 | 2015-02-19 | トリアジン化合物及びその医薬用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015219920A1 AU2015219920A1 (en) | 2016-07-14 |
| AU2015219920B2 true AU2015219920B2 (en) | 2018-12-20 |
Family
ID=53878341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015219920A Ceased AU2015219920B2 (en) | 2014-02-20 | 2015-02-19 | Triazine compound and use thereof for medical purposes |
Country Status (32)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| TWI651310B (zh) * | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| KR102606064B1 (ko) * | 2014-12-24 | 2023-11-27 | 내셔널 인스티튜트 오브 바이올로지칼 사이언시스, 베이징 | 괴사 억제제 |
| WO2016139786A1 (ja) * | 2015-03-04 | 2016-09-09 | 株式会社島津製作所 | 蛍光誘導体化試薬及びアミン分析方法 |
| JP2017039714A (ja) | 2015-08-17 | 2017-02-23 | 日本たばこ産業株式会社 | ヒドロキシトリアジン化合物及びその医薬用途 |
| US10710967B2 (en) | 2015-10-29 | 2020-07-14 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivative |
| GB201603311D0 (en) * | 2016-02-25 | 2016-04-13 | Jakobsson Per Johan | New uses and methods |
| EP3490974B1 (en) * | 2016-08-01 | 2023-12-06 | Tenacia Biotechnology (Hong Kong) Co., Limited | Spiro-lactam nmda receptor modulators and uses thereof |
| KR102538803B1 (ko) | 2016-08-01 | 2023-06-01 | 앱티닉스 인크. | 스피로-락탐 nmda 조정제 및 그의 사용 방법 |
| CN110799506B (zh) * | 2017-06-26 | 2024-03-01 | 默克专利有限公司 | 用于制备被取代的含氮杂环化合物的方法 |
| WO2021016256A2 (en) * | 2019-07-22 | 2021-01-28 | Angion Biomedica Corp. | Ethynylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors |
| US11400100B2 (en) * | 2019-12-11 | 2022-08-02 | Somerset Therapeutics, Llc. | Effective benzalkonium chloride-free bimatoprost ophthalmic compositions |
| KR102157466B1 (ko) * | 2020-05-19 | 2020-09-17 | 동아대학교 산학협력단 | 헥사하이드로트리아진 유도체를 포함하는 방광암의 예방, 개선 또는 치료용 조성물 |
| US20240083867A1 (en) | 2021-02-02 | 2024-03-14 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivative |
| KR20250030486A (ko) | 2022-07-06 | 2025-03-05 | 아스카 세이야쿠 가부시키가이샤 | 피리미딘 유도체 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011037610A1 (en) * | 2009-09-23 | 2011-03-31 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH473818A (de) | 1964-03-18 | 1969-06-15 | Ciba Geigy | Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung |
| WO1981003020A1 (en) * | 1980-04-22 | 1981-10-29 | Commw Scient Ind Res Org | Triazine synthesis |
| SU1313854A1 (ru) | 1985-04-17 | 1987-05-30 | Институт Органической Химии Ан Армсср | Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина |
| DE19543730A1 (de) * | 1995-11-23 | 1997-05-28 | Ciba Geigy Ag | Bis-Resorcinyl-Triazine |
| WO1998024782A2 (en) * | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidine compounds and their use |
| ZA9710727B (en) | 1996-12-05 | 1998-06-12 | Amgen Inc | Substituted pyrimidine compounds and methods of use. |
| AR048564A1 (es) * | 1996-12-05 | 2006-05-10 | Amgen Inc | Compuestos de pirimidina sustituidos,composicion farmaceutica y usos para la fabricacion de medicamentos particularmente para el tratamiento de enfermedades mediadas por tnf-alfa, il-1 beta, il-6 y/o il-8 |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
| GB9726987D0 (en) | 1997-12-22 | 1998-02-18 | Glaxo Group Ltd | Compounds |
| EA004656B1 (ru) | 1999-04-01 | 2004-06-24 | Пфайзер Продактс Инк. | Аминопиримидины в качестве ингибиторов сорбитолдегидрогеназы |
| WO2004000820A2 (en) * | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain aromatic monocycles as kinase modulators |
| ES2398854T3 (es) | 2007-04-03 | 2013-03-22 | E. I. Du Pont De Nemours And Company | Fungicidas de benceno sustituido |
| JP5388270B2 (ja) | 2008-06-04 | 2014-01-15 | 株式会社Ａｄｅｋａ | ２，４，６−トリス（ヒドロキシフェニル）−１，３，５−トリアジン化合物の製造方法 |
| US8716474B2 (en) | 2008-06-04 | 2014-05-06 | Adeka Corporation | Method for producing 2,4,6-tris(hydroxyphenyl)-1,3,5-triazine compound |
| EP2138488A1 (en) | 2008-06-26 | 2009-12-30 | sanofi-aventis | 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases |
| CN101747282A (zh) * | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
| AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| WO2011048004A1 (en) | 2009-10-23 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin e2 synthase-1 |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| AR086254A1 (es) | 2011-05-26 | 2013-11-27 | Lilly Co Eli | Derivados de imidazol utiles para el tratamiento de artritis |
| FR2983859B1 (fr) | 2011-12-12 | 2014-01-17 | Sanofi Sa | Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique |
| AU2013207289B2 (en) * | 2012-01-06 | 2017-09-21 | Les Laboratoires Servier | Therapeutically active compounds and their methods of use |
| CA2873984A1 (en) | 2012-05-23 | 2013-11-28 | Stemergie Biotechnology Sa | Inhibitors of the activity of complex (iii) of the mitochondrial electron transport chain and use thereof |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| JP2014031035A (ja) | 2012-08-01 | 2014-02-20 | Yamaha Motor Co Ltd | 原動機付き鞍乗型車両 |
| WO2015059618A1 (en) * | 2013-10-22 | 2015-04-30 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS |
| TWI651310B (zh) | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| CN105586773A (zh) * | 2014-11-13 | 2016-05-18 | 东丽纤维研究所（中国）有限公司 | 一种拒水抗紫外纺织品及其生产方法和用途 |
| JP2017039714A (ja) | 2015-08-17 | 2017-02-23 | 日本たばこ産業株式会社 | ヒドロキシトリアジン化合物及びその医薬用途 |
| US10710967B2 (en) * | 2015-10-29 | 2020-07-14 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivative |
-
2015
- 2015-02-17 TW TW104105551A patent/TWI651310B/zh not_active IP Right Cessation
- 2015-02-19 AU AU2015219920A patent/AU2015219920B2/en not_active Ceased
- 2015-02-19 PL PL15751885T patent/PL3109240T3/pl unknown
- 2015-02-19 US US14/626,243 patent/US20150266834A1/en not_active Abandoned
- 2015-02-19 SI SI201530563T patent/SI3109240T1/sl unknown
- 2015-02-19 SM SM20180684T patent/SMT201800684T1/it unknown
- 2015-02-19 ES ES15751885T patent/ES2704922T3/es active Active
- 2015-02-19 CN CN201580020793.6A patent/CN106232585B/zh active Active
- 2015-02-19 KR KR1020167025241A patent/KR102360699B1/ko not_active Expired - Fee Related
- 2015-02-19 RU RU2016137263A patent/RU2692789C2/ru active
- 2015-02-19 RS RS20181563A patent/RS58235B1/sr unknown
- 2015-02-19 SG SG11201606902QA patent/SG11201606902QA/en unknown
- 2015-02-19 EP EP18201469.6A patent/EP3456713A1/en not_active Withdrawn
- 2015-02-19 PT PT15751885T patent/PT3109240T/pt unknown
- 2015-02-19 WO PCT/JP2015/054519 patent/WO2015125842A1/ja not_active Ceased
- 2015-02-19 MY MYPI2016703028A patent/MY183605A/en unknown
- 2015-02-19 BR BR112016018341-0A patent/BR112016018341B1/pt not_active IP Right Cessation
- 2015-02-19 CA CA2936408A patent/CA2936408C/en active Active
- 2015-02-19 TR TR2018/21158T patent/TR201821158T4/tr unknown
- 2015-02-19 DK DK15751885.3T patent/DK3109240T3/en active
- 2015-02-19 PE PE2016001506A patent/PE20161236A1/es unknown
- 2015-02-19 LT LTEP15751885.3T patent/LT3109240T/lt unknown
- 2015-02-19 HR HRP20182134TT patent/HRP20182134T1/hr unknown
- 2015-02-19 PE PE2021000546A patent/PE20211548A1/es unknown
- 2015-02-19 MX MX2016010875A patent/MX369217B/es active IP Right Grant
- 2015-02-19 EP EP15751885.3A patent/EP3109240B1/en active Active
- 2015-02-19 AR ARP150100484A patent/AR099498A1/es active IP Right Grant
- 2015-02-19 JP JP2015030157A patent/JP6461637B2/ja active Active
-
2016
- 2016-08-17 IL IL24731916A patent/IL247319B/en active IP Right Grant
- 2016-08-18 SA SA516371701A patent/SA516371701B1/ar unknown
- 2016-08-18 CL CL2016002091A patent/CL2016002091A1/es unknown
- 2016-08-18 PH PH12016501651A patent/PH12016501651B1/en unknown
- 2016-09-19 ZA ZA2016/06449A patent/ZA201606449B/en unknown
-
2018
- 2018-12-19 CY CY20181101359T patent/CY1121261T1/el unknown
- 2018-12-26 JP JP2018241974A patent/JP2019065036A/ja active Pending
-
2019
- 2019-04-26 US US16/396,503 patent/US20200087266A1/en not_active Abandoned
-
2021
- 2021-01-05 JP JP2021000347A patent/JP2021054856A/ja not_active Ceased
-
2022
- 2022-01-14 US US17/575,931 patent/US12398111B2/en active Active
- 2022-06-17 JP JP2022097960A patent/JP2022120173A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011037610A1 (en) * | 2009-09-23 | 2011-03-31 | Albert Einstein College Of Medicine Of Yeshiva University | Prostaglandin transporter inhibitors and uses thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12398111B2 (en) | Triazine compounds and pharmaceutical use thereof | |
| US9096558B2 (en) | N-sulfonylbenzamide compounds | |
| CN101415683B (zh) | 新化合物 | |
| AU2003211617A1 (en) | Ester compound and medicinal use thereof | |
| US9567310B2 (en) | Benzene sulfonamide thiazole compounds | |
| HK1217016A1 (zh) | 作为钙或钠通道阻滞剂的芳基取代羧醯胺衍生物 | |
| WO2009131065A1 (ja) | アリールスルホニル誘導体を有効成分とする長鎖脂肪酸伸長酵素阻害剤 | |
| US12492182B2 (en) | Hydroxytriazine compounds and pharmaceutical use thereof | |
| US10138255B2 (en) | Piperazine derivatives as HIV protease inhibitors | |
| WO1999025712A1 (en) | Novel amide compounds and drugs containing the same | |
| CA3023805A1 (en) | Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors | |
| HK1228389A1 (en) | Triazine compound and use thereof for medical purposes | |
| HK1228389B (en) | Triazine compound and use thereof for medical purposes | |
| NZ721718B2 (en) | Triazine compound and use thereof for medical purposes | |
| WO2021231782A1 (en) | Perk inhibitors for treating viral infections | |
| US20230102520A1 (en) | Inhibitors of low molecular weight protein tyrosine phosphatase (lmptp) and uses thereof | |
| HK1165795A (en) | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |